Sunday, November 29, 2015

Kensey Nash shares down 20 pct. on royalty dispute

The Exton medical device maker said it will enter mediation with St. Jude Medical over the amount of royalties Kensey Nash contends it is owed from sales of the Angio-Seal device.

Kensey Nash shares down 20 pct. on royalty dispute


Shares of Kensey Nash Corp. were down as much as 21 percent Friday morning after the medical device maker said it would enter mediation over a long-running dispute involving royalty payments.

The Exton company has been squabbling with the much bigger St. Jude Medical Inc. over how much Kensey Nash has received from sales of a product called Angio-Seal. That device is used to close wounds after heart-artery surgery.

St. Jude acquired the rights to the Kensey Nash-developed product in 1999.

Kensey Nash contends that St. Jude should have been paying royalties at an 8 percent rate, rather than 6 percent, since 2007. The company estimated that Minnesota-based St. Jude has underpaid Kensey Nash by more than $30 million.

In addition, Kensey Nash said that St. Jude further cut that royalty rate to 2 percent as of November.

In a statement, Kensey Nash CEO Joseph W. Kaufmann said that latest reduction in the royalty rate suggests that St. Jude intends to end all royalty payments in April 2014. But Kensey Nash said it interprets agreements between the two long-time partners as calling for payments to continue at least through April 2016 and possibly through 2023.

Kaufmann said on a conference call that the company expects the mediation process would be completed in 90 to 120 days. The company estimated the value of the intellectual property and royalty payments at stake at $125 million.

Kensey Nash had revenues of $71.6 million in its most recent fiscal year. St. Jude had 2010 net sales of $5.2 billion.

In early afternoon trading, Kensey Nash shares were down $5.59, or 20.9 percent, to $21.11.

Inquirer Columnist
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at

Mike Armstrong Inquirer Columnist
Also on
letter icon Newsletter